IMVT - Immunovant Inc

IMVT - Immunovant Inc

https://immunovant.com

Hold Momentum: Bearish

Recent News

Powered by Alpha Vantage

Immunovant ( IMVT ) Up 7.8% Since Last Earnings Report: Can It Continue?

Zacks Commentary • 5 days ago • score: 0.29

Immunovant (IMVT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

IMVT Stock Up 11% on Upbeat Batoclimab Hyperthyroidism Study Results

Zacks Commentary • 1 week, 4 days ago • score: 0.19

Immunovant stock jumps 11% after new batoclimab study results showed durable thyroid hormone control in Graves' disease patients.

Why Immunovant Stock Blasted Higher Today

Motley Fool • 1 week, 4 days ago • score: 0.26

The biotech looks as if it has a promising treatment for an autoimmune disorder.

Roivant Unveils Durability and Treatment-Free Six-month Remission Data with Potential to Change Treatment Paradigm for Uncontrolled Graves' Disease Patients

GlobeNewswire • 1 week, 4 days ago • score: 0.12

NEW YORK, Sept. 03, 2025 ( GLOBE NEWSWIRE ) -- Immunovant, Inc. ( Nasdaq: IMVT ) , a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today shared an abstract with six-month off-treatment data in uncontrolled Graves' disease ( GD ) ...

Immunovant Unveils Durability and Treatment-Free Six-month Remission Data with Potential to Change Treatment Paradigm for Uncontrolled Graves' Disease Patients

GlobeNewswire • 1 week, 4 days ago • score: 0.14

NEW YORK, Sept. 03, 2025 ( GLOBE NEWSWIRE ) -- Immunovant, Inc. ( Nasdaq: IMVT ) , a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today shared an abstract with six-month off-treatment data in uncontrolled Graves' disease ( GD ) ...

Immunovant's Q1 Loss Narrower Than Expected, Pipeline in Focus

Zacks Commentary • 1 month ago • score: 0.03

IMVT reports a narrower Q1 loss, as spotlight remains on IMVT-1402's broad clinical potential across multiple indications.

Immunovant Posts 34% R&D Jump in Q1

Motley Fool • 1 month ago • score: 0.20

Immunovant ( NASDAQ:IMVT ) , a clinical-stage biotechnology company focused on therapies for autoimmune conditions, reported results for the quarter ended June 30, 2025, on August 11, 2025. Net loss per common share ( GAAP ) was $0.71 in Q1 FY2026.

All You Need to Know About Immunovant ( IMVT ) Rating Upgrade to Buy

Zacks Commentary • 1 month, 4 weeks ago • score: 0.31

Immunovant (IMVT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Downtrend

As of 2025-09-10 (Snapshot)

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. The company is headquartered in New York, New York.

52W High

$34.18

52W Low

$12.72

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

0.44

Valuation

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

N/A

EV/EBITDA (<8 favorable)

-14.12

EV/Revenue (<3 favorable)

N/A

P/S (TTM) (<3 favorable)

N/A

P/B (<3 favorable)

4.91

Ownership

Balanced

Source: Overview

Insiders (1–5% typical)

57.08%

Institutions (25–75% balanced)

55.58%

Shares Outstanding

174,317,000

Float

66,981,000

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

0

Gross Profit (TTM)

0

EPS (TTM)

-2.84

Profit Margin (>10% good)

N/A

Operating Margin (TTM) (higher better)

N/A

ROE (TTM) (>15% strong)

-0.78%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

N/A

Momentum

Bearish momentum

Value

0.2250

Previous

0.2432

Trend

Falling

Signal Cross

No cross

As of

Sep. 12, 2025